Ten Lessons for the Formulation Development of Monoclonal Antibodies from Multimodal Thermal Unfolding Case Studies
|
|
- Doreen Johnston
- 6 years ago
- Views:
Transcription
1 Ten Lessons for the Formulation Development of Monoclonal Antibodies from Multimodal Thermal Unfolding Case Studies Mark Brader Protein Pharmaceutical Development Biogen Idec PEGS Boston essential protein engineering summit May 4-5, 2015
2 Methodology Differential Scanning Calorimetry F ab C p (cal/ o C) C H 2 C H 3
3 Methodology Optim1000 simultaneous fluorescence and light scattering Thermal ramp Intrinsic fluorescence Static light scattering unfolding transition temperature (T m ) aggregation onset temperature (T agg )
4 Methodology DSC + Intrinsic Fluorescence (F350/330) As the first domain unfolds a transition is detected by the fluorescence change
5 Methodology DSC + Static Light Scattering As the second domain unfolds the protein aggregates
6 Methodology DSC SLS F 350/330 Superimposed mab7 screening buffer Fl 350/330 SLS DSC Initiation of fluorescence change coincides with unfolding of first domain Initiation of aggregation coincides with unfolding of second domain
7 In a simple world, where all proteins behave the same, and conventional wisdom applies well to mab formulation development
8 the everything is awesome scenario applies DSC F350/330 Screening buffer C P (cal/mole/ o C) F350/330 SLS SLS Formulated o
9 But unfortunately in the real world of protein product development it s a complicated world and everything is not always awesome
10 #1 A wide range of thermal unfolding profiles and conformational stabilities are observed for developable molecules
11 DSC profiles of 8 developable mabs in citrate buffer C P (cal/mole/ o C) T m (1) range T onset range Large Fab T m range
12 #2 Thermal shifts associated with the first unfolding transition may not correlate with improved pharmaceutical stability
13 DT m ( o C) DT m ( o C) DT m ( o C) Thermal shifts of T m (1) citrate buffer pharmaceutically optimized formulations 6 4 T m (1) DSC 10 8 T onset DSC mab1 mab2 mab3 mab4 mab5 mab6 mab7 mab8-8 mab1 mab2 mab3 mab4 mab5 mab6 mab7 mab8 7 T m (1) F 350/ mab1 mab2 mab3 mab4 mab5 mab6 mab7 mab8
14 #3 Improving thermal stability of the Fab domains may represent a better general formulation strategy than the more common approach of focusing on the first unfolding transition
15 DT m ( o C) Thermal shifts of T m (Fab) citrate buffer pharmaceutically optimized formulations (d) Shifts in Fab T m 6 of 8 mabs show clear positive shifts
16 C P (kcal/mole/ C) C P (kcal/mole/ C) mab2 formulated under conditions that greatly reduced Tm(1) but interestingly Fab Tm did not change importance of the Fab 66.5(±1.0) 73.5(±0.1) 82.3(±0.1) (±0.8) Temperature ( C) 73.5(±0.3) 82.7(±0.2) Temperature ( C) Cp(Y) CpBase(Y) CpFit(Y) CpPk1 CpPk2 CpPk3 Cp(Y) CpBase(Y) CpFit(Y) CpPk1 CpPk2 CpPk3
17 #4 Unusual or anomalous spectroscopic signatures do not necessarily translate into poor pharmaceutical stability
18 Intrinsic fluorescence profiles of 8 mabs in citrate buffer mab1 mab2 mab3 mab5 mab6 F350/330 F350/330 F350/330 F350/330 F350/330 F350/330 mab4 mab7 mab8 F350/330 F350/330
19 mab4 s unusual fluorescence transitions blue shift pre-unfolding transition red shift
20 % Bioactivity mab4 s unusual fluorescence transitions blue shift red shift pre-unfolding transition % Bioactivity after 6 months at 25 o C and after 3 months at 40 o C Excellent stability
21 mab4 s unusual fluorescence transitions blue shift red shift pre-unfolding transition % Aggregate by SE-HPLC 40 o C storage 25 % Bioactivity after 6 months at 25 o C mab1 and after 3 months at 40 o C % Aggregates by SE-HPLC mab2 mab3 mab4 mab5 mab6 mab7 mab8 5 Excellent stability Time (months)
22 #5 T agg does not appear to be a sensitive general indicator of improved formulation stability
23 DT m ( o C) Thermal shifts of T agg by SLS citrate buffer pharmaceutically optimized formulation mab1 mab2 mab3 mab4 mab5 mab6 mab7 mab8
24 #6 Formulation conditions can alter the cooperativity of domain unfolding
25 Formulation conditions can alter the cooperativity of domain unfolding C P (cal/mole/ o C) citrate buffer C P (cal/mole/ o C) pharmaceutically optimized formulation
26 A formulation strategy focused on the first Tm would miss the improved stabilization conferred by this formulation 63.3(±0.1) 70.6(±0.5) 82.6(±0.1) C P (cal/mole/ o C) citrate buffer 60.1(±0.2) 66.2(±0.1) 71.8(±0.1) 82.7(±0.1) C P (cal/mole/ o C) pharmaceutically optimized formulation
27 #7 & #8 Aggregation can be driven by different domains. The least conformationally stable domain is not necessarily the most aggregation-prone Formulation conditions can alter which domain drives aggregation
28 SLS reveals which domain mediates aggregation Formulation conditions can alter which domain drives aggregation mab7 mab4 citrate buffer Second domain aggregates First domain aggregates mab4 formulated formulation optimization Second domain aggregates
29 #9 Stability ranking at high temperature may not translate to pharmaceutically relevant temperatures
30 Poor correlation between Tm(1) and storage stability at 25 o C T m (1) by DSC versus aggregation rate by SE-HPLC at 25 o C for optimized formulations aggregation rate by SE-HPLC (%/month) T m (1) ( o C)
31 Pharmaceutical stability data increase in aggregation by SE-HPLC these developable mabs had <3.6%/month aggregation at 40 o C aggregation kinetics at 5 o C may be non-linear whereas aggregation kinetics at 25 and 40 o C are linear
32 #10 Prediction of low temperature stability from high temperature stability is unreliable
33 Simultaneous Multiple Sample Light Scattering monitoring of mab aggregation Wayne Reed, Tulane University Drenski et al. Analytical Biochemistry 437 (2013)
34 Conclusions Significant diversity in the thermal unfolding profiles mabs possessing a wide range of conformational stabilities and thermal unfolding profiles can be formulated into stable scalable products Formulation conditions shift thermal unfolding transitions Not all excipients confer pharmaceutical stability by increasing conformational stability Consideration of first transitions only can be misleading Stabilization of Fab appears to be more important than stabilization of the first transition
35 Acknowledgments Tia Estey Shujun Bai Roy Alston Karin Lucas Steve Lantz Kevin Maloney Pavel Landsman Reference Examination of Thermal Unfolding and Aggregation Profiles of a Series of Developable Therapeutic Monoclonal Antibodies Mark L. Brader,* Tia Estey, Shujun Bai, Roy W. Alston, Karin K. Lucas, Steven Lantz, Pavel Landsman, Kevin M. Maloney Molecular Pharmaceutics 2015, 12,
Off to the races: rapid buffer exchange, protein quantification and stability screening with Junior, Lunatic and Uncle
Application Note Off to the races: rapid buffer exchange, protein quantification and stability screening with Junior, Lunatic and Uncle Introduction The conformational, chemical and colloidal stability
More informationValue of DSC in characterization and optimization of protein stability as compared to other thermal stability assays
Value of DSC in characterization and optimization of protein stability as compared to other thermal stability assays 韩佩韦 Malvern Instruments 2016.02.28 Complex task of characterization and optimization
More informationStability of sub-unit vaccines measured with the UNit label-free stability platform
Application Note Stability of sub-unit vaccines measured with the UNit label-free stability platform Introduction Sub-unit vaccines and the need for adjuvants Of the many classes of vaccines that have
More informationSummary of Article. Introduction
FORMULATION AND DEVELOPMENT» Automated and Rapid Methods to Assess Quality & Stability of Biologics: Recent Developments and Practical Ways to Implement Them in Formulation Development Summary of Article
More informationWhen proteins are being developed as therapeutics, an important consideration is both the inherent conformational
Using Differential Scanning Calorimetry in Understanding the Correlation Between Thermal Stability and Protein Stability: A Case Study Written by Jie Wen, Yijia Jiang, Kathryn Hymes*, Ke Gong*, and Linda
More informationZetasizer ZS Helix (DLS/Raman) For Characterization of Pharmaceuticals and Biopharmaceuticals
Zetasizer ZS Helix (DLS/Raman) For Characterization of Pharmaceuticals and Biopharmaceuticals Benefits of Zetasizer ZS Helix What it provides Develop mechanistic insight into oligomerization and aggregation
More informationQuantify protein stability with ΔG
Technical Note Quantify protein stability with ΔG Introduction Biologics stability determinations often rely on forced degradation methods to rank constructs or optimize formulations. The most well-established
More informationRegulatory Consideration for the Characterization of HOS in Biotechnology Products
Regulatory Consideration for the Characterization of HOS in Biotechnology Products Maria Teresa Gutierrez Lugo, Ph.D. OBP/CDER/FDA 5 th International Symposium on Higher Order Structure of Protein Therapeutics
More informationFormulation Optimization Using the HUNK
Formulation Optimization Using the HUNK Application Note Measuring ΔG: The Development Pathway to the Optimal Drug Product The development of successful biologics requires formulations that extend shelf
More informationHigh-throughput Biophysical Analysis of Protein Stability: Comparability Assessments and Formulation Development
High-throughput Biophysical Analysis of Protein Stability: Comparability Assessments and Formulation Development David B. Volkin Department of Pharmaceutical Chemistry, Macromolecule and Vaccine Stabilization
More informationnanodsf 2bind: Your service provider for biophysical characterization of proteins Precisely revealing protein folding and stability
nanodsf Precisely revealing protein folding and stability 2bind: Your service provider for biophysical characterization of proteins This booklet was written and designed by 2bind 08 2015 Any reproduction
More informationPrometheus Series Product Information
Prometheus Series Product Information Prometheus Instruments for nanodsf www.nanotemper-technologies.com Prometheus Series NanoTemper Technologies offers nanodsf technology with the Prometheus Series.
More informationPharmaceutical Development for ADCs: Not as Simple as ABC
Pharmaceutical Development for ADCs: Not as Simple as ABC Pharmaceutical Development for ADCs Formulation, process, and analytical development for antibody-drug conjugates, or ADCs, is complex. While the
More informationFormulation Development
Formulation Development Application Note NT-PR-013 Use of iformulate and nanodsf for Fast and Precise Protein Formulation Development Dennis Breitsprecher*, Rajiv Nayar #, *NanoTemper Technologies GmbH,
More informationBest Practices in Formulation and Lyophilization Development Proteins, mabs and ADCs
Best Practices in Formulation and Lyophilization Development Proteins, mabs and ADCs Best Practices in Formulation and Lyophilization Development The ultimate goal of formulation development is a stable
More informationUsing sequence analysis and design to mitigate formulation concerns during pre-clinical development
Using sequence analysis and design to mitigate formulation concerns during pre-clinical development Margaret Ricci, Riki Stevenson, Holly Huang, Francis Kinderman, Heather Franey, Stephen Brych, Xichdao
More informationAutomated Chemical Denaturation as a Tool to Evaluate Protein Stability and Optimize the Formulation of Biologics
Automated Chemical Denaturation as a Tool to Evaluate Protein Stability and Optimize the Formulation of Biologics Ernesto Freire Johns Hopkins University Baltimore, MD 21218 ef@jhu.edu AVIA 2304 Automated
More informationCapillary Electrophoresis Sodium Hexadecyl Sulfate (CE-SHS): A Novel Approach to Evaluate the Purity of Therapeutic Proteins
Capillary Electrophoresis Sodium Hexadecyl Sulfate (CE-SHS): A Novel Approach to Evaluate the Purity of Therapeutic Proteins Jeff Beckman Bristol Myers Squibb 1 OUTLINE 1.CE-SDS: Improvement Opportunities
More informationFORMULATION & LYOPHILIZATION CYCLE DEVELOPMENT OF AN ADC
FORMULATION & LYOPHILIZATION CYCLE DEVELOPMENT OF AN ADC A Case Study Wendy Saffell-Clemmer Director, R&D Baxter BioPharma Solutions Antibody Drug Conjugates (ADCs) are complex molecules consisting of
More informationUse of ITC/DSC for the studies of biomolecularstability and interaction of excipients with proteins. Natalia Markova
Use of ITC/DSC for the studies of biomolecularstability and interaction of excipients with proteins Natalia Markova MIBio2012 Outline Brief intro to the specifics of protein stability profiling and optimization
More informationSuppl. Table I. Design of mutations within the BIIB4 and BIIB5 scfvs for screening in a thermal challenge assay.
Suppl. Table I. Design of mutations within the and scfvs for screening in a thermal challenge assay. scfv position (Kabat numbering) Residue Frequency a Covariation DEEK or Rosetta c scfv position (Kabat
More information3D Structure of Biologics in a Convenient Immunoassay Format
3D Structure of Biologics in a Convenient Immunoassay Format Xing Wang, Ph.D. Array Bridge Inc. 5/25/2017 1 Topics Covered Today Why New Technologies? Technology Development. Case Studies for Novel and
More informationAdvanceBio HIC: a Hydrophobic HPLC Column for Monoclonal Antibody (mab) Variant Analysis
Application Note Biologics Development AdvanceBio HIC: a Hydrophobic HPLC Column for Monoclonal Antibody (mab) Variant Analysis Using the Agilent 16 Infinity II Bio-Inert LC Authors Andrew Coffey and Sandeep
More informationRegulatory Perspectives on Higher Order Structure Evaluations for Protein Products. Emily Shacter, Ph.D.
Regulatory Perspectives on Higher Order Structure Evaluations for Protein Products Emily Shacter, Ph.D. Chief, Laboratory of Biochemistry U.S. Food and Drug Administration Center for Drug Evaluation and
More informationMass Spectrometry for Characterization of Monoclonal Antibodies: Regulatory Considerations
Mass Spectrometry for Characterization of Monoclonal Antibodies: Regulatory Considerations Jun Park, Ph.D. Division of Monoclonal Antibodies Office of Biotechnology Products OPS/CDER Food and Drug Administration
More informationAntibody-Drug Conjugates The Road to the Current State. Nila Das, Ph.D. American Drug Delivery & Formulation Summit San Diego, CA June 13, 2016
Antibody-Drug Conjugates The Road to the Current State Nila Das, Ph.D. American Drug Delivery & Formulation Summit San Diego, CA June 13, 2016 1 Current Status of ADCs C&E News. 2014, 92(3): 13-21 2 Current
More informationOur Solutions for Protein Analysis
Our Solutions for Protein Analysis www.horibalifesciences.com info.sci@horiba.com Solutions for Protein Characterization Kinetics Proteins are involved in many critical roles in the body: Enzymes - allow
More informationAssistant Professor Mohammad A Alsenaidy, MSc, PhD, Saudi Arabia
GaBI Scientific Meetings First GCC Stakeholder Meeting on Approval Process, Interchangeability/Substitution and Safety of Biosimilars 20 November 2017, Holiday Inn Izdihar Riyadh, Saudi Arabia Assistant
More informationChallenges in Optimizing Formulations for Multi- Antigen Vaccines
Engineering Conferences International ECI Digital Archives Vaccine Technology IV Proceedings Spring 5-22-212 Challenges in Optimizing Formulations for Multi- Antigen Vaccines Lakshmi Khandke Pfizer Global
More informationMolecular Characterization of Biotherapeutics The Agilent 1260 Infi nity Multi-Detector Bio-SEC Solution with Advanced Light Scattering Detection
Molecular Characterization of Biotherapeutics The Agilent 126 Infi nity Multi-Detector Bio-SEC Solution with Advanced Light Scattering Detection Application Note Biologics and Biosimilars Authors Sonja
More informationProtein Stability Analysis Using the Optim Patrick Celie NKI Protein Facility, Amsterdam
Protein Stability Analysis Using the Optim 1000 Patrick Celie NKI Protein Facility, Amsterdam NKI Protein Facility Fundamental and translation cancer research ~ 650 scientists + supporting personnel Connected
More informationFc engineering for improved developability and retained biological activity
Fc engineering for improved developability and retained biological activity M. Jack Borrok Antibody Discovery & Protein Engineering Department Medimmune, Gaithersburg MD, USA Knect 365 Antibody Engineering
More informationHigh Throughput Biophysical Approaches to Preformulation Characterization and Comparability Analysis of Protein Drugs and Macromolecular Vaccines
High Throughput Biophysical Approaches to Preformulation Characterization and Comparability Analysis of Protein Drugs and Macromolecular Vaccines David B. Volkin, Ph.D. Higuchi Distinguished Professor
More informationScientific and Regulatory Perspectives on Measuring Protein Aggregation of Biotechnology Products
Scientific and Regulatory Perspectives on Measuring Protein Aggregation of Biotechnology Products Ashutosh Rao, Ph.D. Chief, Laboratory of Applied Biochemistry Division of Biotechnology Review and Research
More informationFormulation Aspects in Biosimilar Development. Kedar S. Gokhale, PhD. Lupin Ltd. (Biotech)
Formulation Aspects in Biosimilar Development Kedar S. Gokhale, PhD. Lupin Ltd. (Biotech) Typical Protein Formulation Components of a protein formulation Active Ingredient Buffer Tonicity modifier Stabilizer
More informationForced Degradation of Protein Therapeutics
Forced Degradation of Protein Therapeutics Wim Jiskoot Division of Drug Delivery Technology Leiden Academic Centre for Drug Research (LACDR) AAPS Annual Meeting Orlando, FL 28 October 2015 Forced degradation
More information1 24 C63 C β- β-
M40 Signal leaved RS1 Domain 59 110 142 Discoidin Domain 223 1 24 63 219 224 + - β- β- M M e e O O H H His 6 -Tag 250 150 100 75 50 37 * 25 20 Supplementary Figure 1 Purification of wild-type retinoschisin.
More informationThermal Analysis. Dr. Lidia Tajber School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin
Thermal Analysis Dr. Lidia Tajber School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin Characterisation for Pharma Active pharmaceutical ingredients (API, drugs) Organic molecules, peptides,
More informationValidation of a Dual Wavelength Size Exclusion HPLC Method with Improved Sensitivity to Detect Aggregates of a Monoclonal Antibody Biotherapeutic
Validation of a Dual Wavelength Size Exclusion HPLC Method with Improved Sensitivity to Detect Aggregates of a Monoclonal Antibody Biotherapeutic By J. Tompkins1, T. Spurgeon 1, R. Tobias 1, J. Anders1,
More informationCharacterization of mab aggregation using a Cary 60 UV-Vis Spectrophotometer and the Agilent 1260 Infinity LC system
Characterization of mab aggregation using a Cary 60 UV-Vis Spectrophotometer and the Agilent 1260 Infinity LC system Application Note Biopharmaceuticals Authors Arunkumar Padmanaban and Sreelakshmy Menon
More informationPhysical Aging and Fragility of Amorphous Sucrose by DSC
Physical Aging and Fragility of Amorphous Sucrose by DSC R. Bruce Cassel, Ph.D. TA Instruments, 109 Lukens Drive, New Castle DE 19720, USA ABSTRACT A method for quantifying physical aging and fragility
More informationStability of Biopharmaceuticals: Past, Present and Future. Paul Varley, Vice President, Biopharmaceutical Development
Stability of Biopharmaceuticals: Past, Present and Future Paul Varley, Vice President, Biopharmaceutical Development Agenda 1 The last 20 years or so 2 Where we are now 3 The future 2 Early Process - THEN
More informationProcess Removal of Impurities in Biotech Products
Process Removal of Impurities in Biotech Products CASSS Midwest Regional Forum October 5, 2017 Warren R. Emery Sr. Research Scientist Bioproduct R&D, Eli Lilly and Company Pharmaceutical Process Development
More informationBiosimilar Monoclonal Antibodies: Registration Requirements. Henry M. J. Leng
Biosimilar Monoclonal Antibodies: Registration Requirements Henry M. J. Leng Disclaimer This presentation is given in my personal capacity and represents only the author s personal views and does not represent
More informationIMPACT OF HIGHER ORDER COMPLEXES ON BIOMARKER TARGET QUANTITATION
IMPACT OF HIGHER ORDER COMPLEXES ON BIOMARKER TARGET QUANTITATION SURENDRAN RAJENDRAN Bristol-Myers Squibb Immunogenicity and Bioassay Summit 2014 - Immunogenicity Assessment & Clinical Relevance - Assay
More informationPeptide libraries: applications, design options and considerations. Laura Geuss, PhD May 5, 2015, 2:00-3:00 pm EST
Peptide libraries: applications, design options and considerations Laura Geuss, PhD May 5, 2015, 2:00-3:00 pm EST Overview 1 2 3 4 5 Introduction Peptide library basics Peptide library design considerations
More informationStructural basis of a novel PD-L1 nanobody for immune checkpoint blockade
Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade Supplementary Materials Supplementary methods Table S1-S Figure S1-S 1 1 1 1 1 1 1 1 1 0 1 0 Supplementary Methods Competitive
More informationLocalized Higher Order Structures of mabs and ADCs Investigated by MS-based Protein Footprinting
Localized Higher Order Structures of s and ADCs Investigated by MS-based Protein Footprinting Lucy Pan, John Valliere-Douglass and Oscar Salas-Solano 6 th International Symposium on the Higher Order Structure
More informationPurification strategies and platform alternatives for monoclonal antibodies
Purification strategies and platform alternatives for monoclonal antibodies Annika Forss, Anna Grönberg, Anders Ljunglöf, Karin Torstenson GE Healthcare Life Sciences, Björkgatan 30, SE-751 84 Uppsala,
More informationAAPS Short Course: Characterization Methods for Aggregates and Particles in Peptide and Small Protein Formulations
AAPS Short Course: Characterization Methods for Aggregates and Particles in Peptide and Small Protein Formulations Sunday, October 25, 2015 Orange County Convention Center Orlando, Florida Logistics AAPS
More informationA Comprehensive Workflow to Optimize and Execute Protein Aggregate Studies
A Comprehensive Workflow to Optimize and Execute Protein Aggregate Studies Combining Size Exclusion Chromatography with Method Development and Light Scattering Application Note Biotherapeutics and Biosimilars
More informationLabChip GXII: Antibody Analysis
WHITE PAPER LabChip GXII: Antibody Analysis Antibody Analysis using microfluidic technology in high throughput Quality by Design Experiments Abstract Current initiatives in Process Analytical Technology
More informationBiosimilar Profiling Application Note NT-PR-010
Biosimilar Profiling Application Note NT-PR-010 Rapid and Precise Biosimilar Candidate Profiling by nanodsf Dennis Breitsprecher 1, Florian Beck 2 and Lukasz Kacprzyk 2 1 NanoTemper Technologies GmbH,
More informationProtein Therapeutics. Novo Nordisk Måløv. Outline
Protein Therapeutics Mats Reslow Novo Nordisk Novo Nordisk Måløv Mats Reslow Protein Structure & Biophysics ProteinTechnology Biopharmaceutical Research Outline Proteins as therapeutics 3 examples on Protein
More informationDrivers and Challenges of Developing High Concentration Injectables 7 th Annual PFS & Injectable Summit September 2017
Drivers and Challenges of Developing High Concentration Injectables 7 th Annual PFS & Injectable Summit 27-28 September 2017 Willow DiLuzio, Ph.D. Director, Formulation and Device Development OVERVIEW
More informationQuantitation of amorphous content
13 Quantitation of amorphous content Amorphous fractions can significantly change the physicochemical properties of active pharmaceutical ingredients and drug products. Solvias offers a variety of analytical
More informationComparability Analysis of Protein Therapeutics by Bottom-Up LC-MS with Stable Isotope-Tagged Reference Standards
Comparability Analysis of Protein Therapeutics by Bottom-Up LC-MS with Stable Isotope-Tagged Reference Standards 16 September 2011 Abbott Bioresearch Center, Worcester, MA USA Manuilov, A. V., C. H. Radziejewski
More informationEAG.COM MATERIALS SCIENCES APPLICATION NOTE. By J. Tompkins 1, T. Spurgeon 1, R. Tobias 1, J. Anders 1, E. Butler-Roberts 2, and M.
MATERIALS SCIENCES NOW WHETHER THE LINER IS THE PROBLEM? HOW DO YOU EVALUATE HYDROPHOBIC COMPOUNDS BY SPME? HOW DO YOU COMPARE FEEDSTOCK SUPPLIERS? O YOU COMPLY WITH ? HOW DO YOU ADDRESS AN
More informationElectronic Supplementary Information for The effect of protein concentration on the viscosity of a recombinant albumin solution formulation
Electronic Supplementary Material (ESI) for RSC Advances. This journal is The Royal Society of Chemistry 2016 Electronic Supplementary Information for The effect of protein concentration on the viscosity
More information9/16/2011. Fluorescent Dye-based Methods to Detect Changes in Higher Order Structures. Protein aggregation
9/16/211 Fluorescent Dye-based Methods to Detect Changes in Higher Order Structures Wim Jiskoot native protein native stressed protein + bound dye intermediate unfolded unbound dye partially unfolded aggregate
More informationPhysical pharmacy. dr basam al zayady
Physical pharmacy Lec 5 dr basam al zayady Liquefaction of Gases: When a gas is cooled, it loses some of its kinetic energy in the form of heat, and the velocity of the molecules decreases. If pressure
More informationBioConvergence Technical Paper
BioConvergence Technical Paper # 2012001 Application of Thermal Analysis in Lyophilization Development and Optimization Kara Strass* and Kelly L. Zaleski, Ph.D.* *BioConvergence LLC, 4320 West Zenith Drive,
More informationIdentification of Critical Product Quality Attributes: Impact of Product Variants on Safety and Efficacy
Identification of Critical Product Quality Attributes: Impact of Product Variants on Safety and Efficacy Ziping Wei, Ph.D. Analytical Biochemistry MedImmune January 25, 2010 Outline Why do we need to identify
More informationAccelerating the development of optimized therapeutic protein formulations using Differential Scanning Calorimetry
Accelerating the development of optimized therapeutic protein formulations using Differential Scanning Calorimetry LABEL-FREE ANALYSIS MICROCALORIMETRY Biomolecules for therapeutic use must be stabilized
More informationCONSEQUENCES OF SAMPLE AGE ON BIOTHERAPEUTIC HIGHER ORDER STRUCTURE: INSIGHTS FROM NATIVE ION MOBILITY-MASS SPECTROMETRY METHODS
COSEQUECES OF SAMPLE AGE O BIOTHERAPEUTIC HIGHER ORDER STRUCTURE: ISIGHTS FROM ATIVE IO MOBILITY-MASS SPECTROMETRY METHODS Richard Kerr ORISE Post-Doctoral Fellow US FDA, Division of Pharmaceutical Analysis
More informationAnalytical Tools for Reliable Detection and Characterization of Protein Particles. Alla Polozova Analytical Biochemistry, MedImmune
Analytical Tools for Reliable Detection and Characterization of Protein Particles Alla Polozova Analytical Biochemistry, MedImmune Outline What to expect: Types of particles which might be present in protein
More informationSupporting Information
Supporting Information Chan et al. 10.1073/pnas.0903849106 SI Text Protein Purification. PCSK9 proteins were expressed either transiently in 2936E cells (1), or stably in HepG2 cells. Conditioned culture
More informationMICROCAL PEAQ-DSC BIOMOLECULAR STABILITY ANALYSIS FOR THE REGULATED ENVIRONMENT LABEL-FREE ANALYSIS MICROCALORIMETRY
LABEL-FREE ANALYSIS MICROCALORIMETRY MICROCAL PEAQ-DSC BIOMOLECULAR STABILITY ANALYSIS FOR THE REGULATED ENVIRONMENT Biomolecular stability analysis for the regulated environment INTRODUCTION TO DIFFERENTIAL
More informationARBRE-P4EU Consensus Protein Quality Guidelines for Biophysical and Biochemical Studies Minimal information to provide
ARBRE-P4EU Consensus Protein Quality Guidelines for Biophysical and Biochemical Studies Minimal information to provide Protein name and full primary structure, by providing a NCBI (or UniProt) accession
More informationUnderstanding the Effects of Common Mobile Phase Additives on the Performance of Size Exclusion Chromatography
Understanding the Effects of Common Mobile Phase Additives on the Performance of Size Exclusion Chromatography 1 Presentation Importance of aggregate analysis in BioPharma manufacturing Analytical techniques
More informationPractical Considerations in Developing High Concentration Antibody Formulations
Practical Considerations in Developing High Concentration Antibody Formulations Qingyan Hu Formulation Development Group Regeneron Pharmaceuticals DDF Summit, 28 29 Aug 2017 Outline High concentration
More informationPerformance of a fast Surface Plasmon Resonance based MAb quantification method
Performance of a fast Surface Plasmon Resonance based MAb quantification method T. Björkman, E. Monié and T. Eriksson GE Healthcare Bio-Sciences AB, R&D, Björkgatan 30, SE-751 84 Uppsala, Sweden First
More informationA complete single-use manufacturing process of monoclonal antibodies: a case study
A complete single-use manufacturing process of monoclonal antibodies: a case study Jakob Liderfelt, Janne Simola, Annika Forss, Gustav Rodrigo, Karin Torstensson, Tomas Björkman, Kjell Eriksson, Hans J
More informationDavid Volkin. Department of Pharmaceutical Chemistry, Macromolecule and Vaccine Stabilization Center
New Analytical Approaches and Data Visualization Tools to Assess Protein Higher-Order Structure and Stability as Applied to Comparability Assessments David Volkin Department of Pharmaceutical Chemistry,
More informationWhat is an Aptamer? smallest unit of repeating structure
What is an Aptamer? apto: mer: to fit smallest unit of repeating structure Aptamers are single stranded folded oligonucleotides that bind to molecular (protein) targets with high affinity and specificity
More informationPHARMACEUTICAL TECHNOLOGY REPORT. Introduction. Methods
PHARMACEUTICAL TECHNOLOGY REPORT Consumer Specialties ashland.com PTR-092 Page 1 of 7 Plasticizer Compatibility and Thermal and Rheological Properties of Plasdone povidone And copovidone polymers for Hot-melt
More informationD e c N o. 2 8
D e c. 2 0 0 7 N o. 2 8 CONFOCAL APPLICATION LETTER resolution FRET Acceptor Photobleaching LAS AF Application Wizard FRET with Leica TCS SP5 LAS AF Version 1.7.0 Introduction Fluorescence Resonance Energy
More informationProcess Validation of a Multi-SKU Drug Product Kevin Maloney, PhD Biogen, Technical Development, Cambridge, MA
Process Validation of a Multi-SKU Drug Product Kevin Maloney, PhD Biogen, Technical Development, Cambridge, MA CASSS CMC Forum, DP Validation, July 2016, Gaithersburg, MD 1 Multi-SKU, Weight-Based, DPs
More informationPhage Antibody Selection With Reichert SPR System
Phage Antibody Selection With Reichert SPR System Reichert Technologies Webinar April 4, 2016 Mark A. Sullivan, Ph.D. Department of Microbiology and Immunology University of Rochester Presentation Outline
More informationCHAPTER 1 INTRODUCTION
CHAPTER 1 INTRODUCTION CHAPTER - 1 1.0 INTRODUCTION In the world of pharmaceutical analysis, the analyst s job mainly revolves around analysis of the Active Pharmaceutical Ingredient (API) or the finished
More informationENZYME CATALYSTS FOR A BIOTECHNOLOGY-BASED CHEMICAL INDUSTRY
ENZYME CATALYSTS FOR A BIOTECHNOLOGY-BASED CHEMICAL INDUSTRY Professor Frances H. Arnold California Institute of Technology DOE Contract DE-FG02-93CH10578 Quarterly Progress Report, September 29 - December
More informationDevelopment of High Concentration cetuximab Formulations using Ultrafiltration and Precipitation Techniques
Dissertation zur Erlangung des Doktorgrades der Fakultat fur Chemie und Pharmazie der Ludwig-Maximilians-Universitat Munchen Development of High Concentration cetuximab Formulations using Ultrafiltration
More informationAutomated platform buffer screening for multiple proteins on Big Kahuna
Application te Automated platform buffer screening for multiple proteins on Big Kahuna Introduction The critical process of screening formulation buffers to optimize stability is labor-intensive and time-consuming,
More informationSUPPLEMENTARY INFORMATION
A biomimetic DNA-based channel for the ligand-controlled transport of charged molecular cargo across a biological membrane Jonathan R. Burns, Astrid Seifert, Niels Fertig, Stefan Howorka NATURE NANOTECHNOLOGY
More informationSeparation of Monoclonal Antibodies Using TSKgel HPLC Columns
ANALYSIS S e p a r a t i o n R e p o r t N o. 7 4 Separation of Monoclonal Antibodies Using TSKgel HPLC Columns Table of Contents 1. Introduction 1 2. Separation Mode and Purification Method 1 3. Applications
More informationG measure stability ΔG trend predict aggregation K D small molecule affinity
Make stability routine The HUNK makes what wasn t possible before routine measurement of protein stability in different formulations using chemical denaturation totally doable. It ll up your insight into
More informationDegradation of Biological Products and Impact on Higher Order Structure
Degradation of Biological Products and Impact on Higher Order Jason K. Cheung, BioProcess Development Biologics and Vaccines Date: May 16, 2016 AAPS-NBC Sunrise Session Analytical Toolkit 2 Analytical
More informationChapter 4. Antigen Recognition by B-cell and T-cell Receptors
Chapter 4 Antigen Recognition by B-cell and T-cell Receptors Antigen recognition by BCR and TCR B cells 2 separate functions of immunoglobulin (Ig) bind pathogen & induce immune responses recruit cells
More informationFluorescent dyes as tools to detect changes in higher order. protein structures
Fluorescent dyes as tools to detect changes in higher order Wim Jiskoot protein structures native stressed protein + bound dye protein native intermediate unfolded unbound dye partially unfolded aggregate
More informationIdentifying Differences in Solution Conformations of Two Chimeric IgG3 Antibodies through Triple Detection SEC
64 LCGC NORTH AMERICA VOLUME 24 NUMBER 1 JANUARY 2006 www.chromatographyonline.com Identifying Differences in Solution Conformations of Two Chimeric IgG3 Antibodies through Triple Detection SEC Size exclusion
More informationCryoconcentration effects during freeze/thaw processing of bulk protein, and possible consequences of frozen storage on protein aggregation
Cryoconcentration effects during freeze/thaw processing of bulk protein, and possible consequences of frozen storage on protein aggregation Satish K Singh 20 July 2010 Abstract Frozen storage of proteins
More informationResearch supervisors Thermal Fluctuation Spectroscopy
Synopsis of thesis titled Thermal Fluctuation Spectroscopy and its application in the study of Biomolecules K. S. Nagapriya Department of Physics, Indian Institute of Science, Bangalore - 560012, INDIA.
More informationParticulates Testing; Requirements and Challenges. Paul G. Varley, VP Development, MedImmune Ltd., Cambridge, UK
Particulates Testing; Requirements and Challenges Paul G. Varley, VP Development, MedImmune Ltd., Cambridge, UK The Simple Stuff Many antibodies form particulates Visible (and sub-visible) Particulates
More informationApplication Note. Authors. Abstract. Biopharmaceuticals
Characterization of monoclonal antibodies on the Agilent 126 Infinity Bio-inert Quaternary LC by Size Exclusion Chromatography using the Agilent BioSEC columns Application Note Biopharmaceuticals Authors
More informationThermo Scientific MAbPac HIC Columns. Novel Hydrophobic Interaction HPLC Columns. Designed for Monoclonal Antibody Analysis
Thermo Scientific MAbPac HIC Columns Novel Hydrophobic Interaction HPLC Columns Designed for Monoclonal Antibody Analysis Introduction The Thermo Scientific MAbPac HIC column family is designed for separations
More informationBiochromatography Bring more Zen into your life and laboratory
Seminar Biochromatography Bring more Zen into your life and laboratory Method development and maintaining peptide, protein, glycan and anti-body analyses by LC or LC-MS can be very time consuming and might
More informationAnalysis of Intact and C-terminal Digested IgG1 on an Agilent Bio MAb 5 µm Column
Analysis of Intact and C-terminal Digested IgG1 on an Agilent Bio MAb µm Column Application Note BioPharma Authors Xiaomi Xu and Phu T Duong Agilent Technologies, Inc. Abstract Nearly all proteins undergo
More informationMeet Big Tuna: automated, versatile buffer exchange
Application Note Meet Big Tuna: automated, versatile buffer exchange Introduction The critical process of screening formulation buffers to optimize stability is labor intensive and time-consuming, which
More informationMolecular recognition
Lecture 9 Molecular recognition Antoine van Oijen BCMP201 Spring 2008 Structural principles of binding 4 fundamental functions of proteins: 1) Binding 2) Catalysis 3) Switching 4) Structural All involve
More informationDiscovery and Humanization of Novel High Affinity Neutralizing Monoclonal Antibodies to Human IL-17A
Discovery and Humanization of Novel High Affinity Neutralizing Monoclonal Antibodies to Human IL-17A Contacts: Marty Simonetti martysimonetti@gmail.com Kirby Alton kirby.alton@abeomecorp.com Rick Shimkets
More information